Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention
نویسندگان
چکیده
منابع مشابه
randomized, blinded trial comparing enoxaparin with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention
background: this study was designed to examine a unique and low dose use of intravenous enoxaparin in elective percutaneous coronary intervention (pci) that would be applicable to an unselected population regardless of age, weight, and renal function. there is limited experience in anticoagulation using intravenous low-molecular-weight heparin in pci. methods: a total of 100 consecutive patient...
متن کاملEfficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
OBJECTIVE To determine the efficacy and safety of enoxaparin compared with unfractionated heparin during percutaneous coronary intervention. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline and Cochrane database of systematic reviews, January 1996 to May 2011. STUDY SELECTION Randomised and non-randomised studies comparing enoxaparin with unfractionated heparin during perc...
متن کامل[Commentary to the article: Montalescot G, White HD, Gallo R, et al. STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention].
BACKGROUND Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI. METHODS In this pros...
متن کاملPercutaneous Intervention and Anticoagulation Outcome of Urgent and Elective Percutaneous Coronary Interventions After Pharmacologic Reperfusion With Tenecteplase Combined With Unfractionated Heparin, Enoxaparin, or Abciximab
Christophe L. Dubois, MD,* Ann Belmans, MSC,*† Christopher B. Granger, MD, FACC,‡ Paul W. Armstrong, MD, FACC,§ Lars Wallentin, MD, FACC, Paolo M. Fioretti, MD, FACC,¶ José L. López-Sendón, MD, FACC,# Freek W. Verheugt, MD, FACC,** Jürgen Meyer, MD, FACC,†† Frans Van de Werf, MD, FACC,* on behalf of the ASSENT-3 Investigators Leuven, Belgium; Durham, North Carolina; Edmonton, Canada; Uppsala, S...
متن کاملHeparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
Bivalirudin, a direct thrombin inhibitor, was developed as an antithrombin agent for patients undergoing percutaneous coronary interventions (PCI) with the hypothesis that it would reduce bleeding complications without compromising the rate of ischemic events compared to heparin plus GP IIb/IIIa inhibitors. Although the cumulative evidence makes a strong argument for the use of bivalirudin rath...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Cardiovascular Interventions
سال: 2009
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2009.08.016